Dosing & Uses
Dosage Forms & Strengths
capsule, macrocrystals
- 25mg
- 50mg
- 100mg
capsule, monohydrate/macrocystals
- 100 mg
oral suspension
- 25mg/5mL
Urinary Tract Infection
Susceptible strains of Escherichia coli, Enterobacter spp, Klebsiella spp, Staphylococcus aureus, and S saprophyticus
Macrocrystals (Macrodantin, Furadantin, and equivalents): 50-100 mg PO q6hr for 7 days or for 3 days after obtaining sterile urine
Monohydrate/macrocrystals (Macrobid and equivalents): 100 mg PO q12hr for 7 days or for 3 days after obtaining sterile urine
Long-term prophylaxis/suppression: 50-100 mg macrocrystals PO HS for up to 12 months
Dosing Considerations
Avoid for long-term UTI suppression; possible pulmonary toxicity; safer alternatives are available
Not drug of choice in elderly because of unfavorable side-effect profile
Loses effectiveness in patients with CrCl <60 mL/min due to inadequate urine concentration (Beers criteria)
Monitor renal function; renally excreted; decreased renal function more likely in elderly
Monitor liver function and possible pulmonary reactions
Take with food or milk
Dual release macrocrystals indicated only for patients >12 years for acute UTIs (cystitis) caused by E coli or S saprophyticus
Dosage Forms & Strengths
capsule, macrocrystals
- 25mg
- 50mg
- 100mg
capsule, monohydrate/macrocrystals
- 100 mg
oral suspension
- 25mg/5mL
Urinary Tract Infection
>1 month
- 5-7 mg/kg/day PO divided q6hr for 7 days
- UTI prophylaxis: 1-2 mg/kg PO qHS or 2 divided doses
>12 years
- Macrocrystals (Macrodantin, Furadantin, and equivalents): 50-100 mg PO q6hr for 7 days or for 3 days after obtaining sterile urine
- Monohydrate/macrocrystals (Macrobid and equivalents): 100 mg PO q12hr for 7 days or for 3 days after obtaining sterile urine
- Long-term prophylaxis/suppression: 50-100 mg macrocrystals PO HS for up to 12 months
Dosing Considerations
Avoid for long-term UTI suppression; possible pulmonary toxicity; safer alternatives are available
Loses effectiveness in patients with CrCl <60 mL/min due to inadequate urine concentration (Beers criteria)
Monitor renal function; renally excreted; decreased renal function more likely in elderly
Monitor liver function
Take with food or milk
Dual release macrocrystals indicated only for patients >12 years for acute UTIs (cystitis) caused by E coli or S saprophyticus
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (0)
Serious - Use Alternative (10)
- BCG vaccine live
nitrofurantoin decreases effects of BCG vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
- cholera vaccine
nitrofurantoin, cholera vaccine. pharmacodynamic antagonism. Avoid or Use Alternate Drug. Avoid coadministration of cholera vaccine with systemic antibiotics since these agents may be active against the vaccine strain. Do not administer cholera vaccine to patients who have received oral or parenteral antibiotics within 14 days prior to vaccination.
- darolutamide
darolutamide will increase the level or effect of nitrofurantoin by Other (see comment). Avoid or Use Alternate Drug. Darolutamide is a BCRP inhibitor. Avoid coadministration with BCRP inhibitors. If use is unavoidable, closely monitor for adverse reactions and consider dose reduction of BCRP substrate drug (refer BCRP substrate prescribing information).
- lasmiditan
lasmiditan increases levels of nitrofurantoin by Other (see comment). Avoid or Use Alternate Drug. Comment: Lasmiditan inhibits BCRP in vitro. Avoid coadministration of lasmiditan with BCRP substrates.
- leniolisib
leniolisib will increase the level or effect of nitrofurantoin by Other (see comment). Avoid or Use Alternate Drug. Leniolisib, a BCRP inhibitor, may increase systemic exposure of BCRP substrates
- microbiota oral
nitrofurantoin decreases effects of microbiota oral by pharmacodynamic antagonism. Avoid or Use Alternate Drug. Microbiota oral contains bacterial spores. Antibacterial agents may decrease efficacy if coadministered. Complete antibiotic regimens 2-4 days before initiating microbiota oral. .
- pexidartinib
nitrofurantoin and pexidartinib both increase Other (see comment). Avoid or Use Alternate Drug. Pexidartinib can cause hepatotoxicity. Avoid coadministration of pexidartinib with other products know to cause hepatoxicity.
- pretomanid
nitrofurantoin, pretomanid. Either increases toxicity of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Pretomanid regimen associated with hepatotoxicity. Avoid alcohol and hepatotoxic agents, including herbal supplements and drugs other than bedaquiline and linezolid.
- selinexor
selinexor, nitrofurantoin. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.
- typhoid vaccine live
nitrofurantoin decreases effects of typhoid vaccine live by pharmacodynamic antagonism. Contraindicated. Wait until Abx Tx complete to administer live bacterial vaccine.
Monitor Closely (38)
- acalabrutinib
acalabrutinib increases levels of nitrofurantoin by Other (see comment). Use Caution/Monitor. Comment: Acalabrutinib may increase exposure to coadministered BCRP substrates by inhibition of intestinal BCRP.
- aluminum hydroxide
aluminum hydroxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- apalutamide
apalutamide will decrease the level or effect of nitrofurantoin by increasing elimination. Use Caution/Monitor. Apalutamide weakly induces BCRP and may decrease systemic exposure of drugs that are BCRP substrates.
- bazedoxifene/conjugated estrogens
nitrofurantoin will decrease the level or effect of bazedoxifene/conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- bupivacaine implant
nitrofurantoin, bupivacaine implant. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Local anesthetics may increase the risk of developing methemoglobinemia when concurrently exposed to drugs that also cause methemoglobinemia.
- calcium carbonate
calcium carbonate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- conjugated estrogens
nitrofurantoin will decrease the level or effect of conjugated estrogens by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- dapsone topical
nitrofurantoin increases toxicity of dapsone topical by altering metabolism. Modify Therapy/Monitor Closely. May induce methemoglobinemia.
- didanosine
didanosine will increase the level or effect of nitrofurantoin by increasing gastric pH. Applies only to oral form of both agents. Use Caution/Monitor. Applies to didanosine chewable tablets and powder for oral solution; administer 2 hr before or several hours after didanosine oral solution or chewable tablet administration
- digoxin
nitrofurantoin will increase the level or effect of digoxin by altering intestinal flora. Applies only to oral form of both agents. Use Caution/Monitor.
- eluxadoline
eluxadoline increases levels of nitrofurantoin by decreasing metabolism. Use Caution/Monitor. Eluxadoline may increase the systemic exposure of coadministered BCRP substrates.
- estradiol
nitrofurantoin will decrease the level or effect of estradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estrogens conjugated synthetic
nitrofurantoin will decrease the level or effect of estrogens conjugated synthetic by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- estropipate
nitrofurantoin will decrease the level or effect of estropipate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- ethinylestradiol
nitrofurantoin will decrease the level or effect of ethinylestradiol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- fostemsavir
fostemsavir will increase the level or effect of nitrofurantoin by Other (see comment). Modify Therapy/Monitor Closely. Fostemsavir inhibits BCRP transporters. If possible, avoid coadministration or modify dose of BCRP substrate coadministered with fostemsavir.
- glecaprevir/pibrentasvir
glecaprevir/pibrentasvir will increase the level or effect of nitrofurantoin by decreasing metabolism. Use Caution/Monitor. Glecaprevir/pibrentasvir may increase plasma concentration of BCRP substrates.
- levonorgestrel oral/ethinylestradiol/ferrous bisglycinate
nitrofurantoin will decrease the level or effect of levonorgestrel oral/ethinylestradiol/ferrous bisglycinate by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor. Antibiotics may decrease hormonal contraceptive efficacy.
- mestranol
nitrofurantoin will decrease the level or effect of mestranol by altering intestinal flora. Applies only to oral forms of hormone. Low risk of contraceptive failure. Use Caution/Monitor.
- mipomersen
mipomersen, nitrofurantoin. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Both drugs have potential to increase hepatic enzymes; monitor LFTs.
- momelotinib
momelotinib increases toxicity of nitrofurantoin by plasma protein binding competition. Modify Therapy/Monitor Closely. Momelotinib (BCRP inhibitor) may increase exposure of BCRP substrates, which may increase the risk of BCRP substrate adverse reactions. Dose adjustment of other BCRP substrates may necessary.
- oteseconazole
oteseconazole will increase the level or effect of nitrofurantoin by Other (see comment). Modify Therapy/Monitor Closely. Otesezonale, a BCRP inhibitor, may increase the effects and risk of toxicities of BCRP substrates. Use lowest starting dose of BCRP substrate, or consider reducing BCRP substrate dose.
- oxybutynin
oxybutynin increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.
- oxybutynin topical
oxybutynin topical increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.
- oxybutynin transdermal
oxybutynin transdermal increases levels of nitrofurantoin by unspecified interaction mechanism. Use Caution/Monitor.
- ponatinib
ponatinib increases levels of nitrofurantoin by Other (see comment). Use Caution/Monitor.
- regorafenib
regorafenib will increase the level or effect of nitrofurantoin by Other (see comment). Modify Therapy/Monitor Closely. Regorafenib likely inhibits BCRP (ABCG2) transport. Coadministration with a BCRP substrate may increase systemic exposure to the substrate and related toxicity.
- safinamide
safinamide will increase the level or effect of nitrofurantoin by Other (see comment). Use Caution/Monitor. Safinamide and its major metabolite may inhibit intestinal BCRP. Monitor BCRP substrates for increased pharmacologic or adverse effects.
- sodium bicarbonate
sodium bicarbonate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- sodium citrate/citric acid
sodium citrate/citric acid decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Separate by 2 hours.
- sodium picosulfate/magnesium oxide/anhydrous citric acid
nitrofurantoin decreases effects of sodium picosulfate/magnesium oxide/anhydrous citric acid by altering metabolism. Use Caution/Monitor. Coadministration with antibiotics decreases efficacy by altering colonic bacterial flora needed to convert sodium picosulfate to active drug.
- sofosbuvir/velpatasvir
sofosbuvir/velpatasvir will increase the level or effect of nitrofurantoin by Other (see comment). Use Caution/Monitor. Velpatasvir is an inhibitor of the drug transporter BCRP. Coadministration may increase systemic exposure of drugs that are BCRP substrates.
- stiripentol
stiripentol will increase the level or effect of nitrofurantoin by Other (see comment). Modify Therapy/Monitor Closely. Stiripentol is a BCRP transport inhibitor. Consider dosage reduction for BCRP substrates if adverse effects are experienced when coadministered.
- tafamidis
tafamidis will increase the level or effect of nitrofurantoin by Other (see comment). Use Caution/Monitor. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Dosage adjustment of these BCRP substrates may be necessary.
- tafamidis meglumine
tafamidis meglumine will increase the level or effect of nitrofurantoin by Other (see comment). Use Caution/Monitor. Tafamidis inhibits breast cancer resistant protein (BCRP) in vitro and may increase exposure of BCRP substrates following tafamidis or tafamidis meglumine administration. Dosage adjustment of these BCRP substrates may be necessary.
- tetracaine
tetracaine, nitrofurantoin. Other (see comment). Use Caution/Monitor. Comment: Monitor for signs of methemoglobinemia when methemoglobin-inducing drugs are coadministered.
- trimagnesium citrate anhydrous
trimagnesium citrate anhydrous decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of nitrofurantoin; administer nitrofurantoin at least 2 hr before or 6 hr after magnesium; use alternatives if available.
- valoctocogene roxaparvovec
nitrofurantoin and valoctocogene roxaparvovec both increase Other (see comment). Use Caution/Monitor. Medications that may cause hepatotoxicity when combined with valoctogene roxaparvovec may potentiate the risk of elevated liver enzymes. Closely monitor these medications and consider alternative medications in case of potential drug interactions.
Minor (14)
- balsalazide
nitrofurantoin will decrease the level or effect of balsalazide by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- biotin
nitrofurantoin will decrease the level or effect of biotin by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- didanosine
didanosine, nitrofurantoin. Either increases toxicity of the other by pharmacodynamic synergism. Minor/Significance Unknown. Enhanced risk of peripheral neuropathy.
- encorafenib
encorafenib will increase the level or effect of nitrofurantoin by Other (see comment). Minor/Significance Unknown. Encorafenib (a BCRP inhibitor) may increase the concentration and toxicities of BCRP substrates. Closely monitor for signs and symptoms of increased exposure and consider adjusting the dose of these substrates.
- magnesium chloride
magnesium chloride decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- magnesium citrate
magnesium citrate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- magnesium hydroxide
magnesium hydroxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- magnesium oxide
magnesium oxide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- magnesium sulfate
magnesium sulfate decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- metoclopramide
metoclopramide decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.
- pantothenic acid
nitrofurantoin will decrease the level or effect of pantothenic acid by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine
nitrofurantoin will decrease the level or effect of pyridoxine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- pyridoxine (Antidote)
nitrofurantoin will decrease the level or effect of pyridoxine (Antidote) by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
- thiamine
nitrofurantoin will decrease the level or effect of thiamine by altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.
Adverse Effects
Frequency Not Defined
Suspected adverse reactions, contact Casper Pharma LLC. at 1-844-5-CASPER (1-844-522-7737) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Anorexia
Arthralgia
Chest pains
Chills
Cough
Clostridium difficile colitis
Cyanosis secondary to methemoglobinemia
Diarrhea
Dizziness
Drowsiness
Dyspnea
Exfoliative dermatitis
Fatigue
Fever
Flatulence
Headache
Hemolytic anemia
Hepatitis
Increased LFTs
Itching
Nausea
Numbness
Paresthesia
Rash
Sore throat
Stomach upset
Vomiting
Weakness
Urine discoloration
Vasculitis
Warnings
Contraindications
Renal failure (anuria, oliguria, or CrCl <60 mL/min)
Pregnancy at term (38-42 weeks of gestation)
History of hepatic dysfunction/cholestatic jaundice with nitrofurantoin
Neonates (<28 days)
Hypersensitivity
Cautions
Caution in patients with G6PD deficiency (may increase risk for hemolytic anemia)
Avoid long-term use in the elderly (may increase risk for pulmonary toxicity)
Renal impairment
Discontinue if paresthesia or hemolysis develop
Risk of occasional hepatotoxicity and pulmonary toxicity
Protect from light
Peripheral neuropathy may occur; risk may increase in patients diagnosed with anemia, diabetes, vitamin B deficiency, or electrolyte imbalance (use caution)
Acute/chronic pulmonary reactions (eg., cough, interstitial pneumonitis or fibrosis) reported
Bacterial superinfections may occur with prolonged treatment
Pregnancy & Lactation
Pregnancy category: B; contraindicated at term
Crosses placenta, but not well distributed
Lactation: Enters breast milk; discontinue drug or do not nurse
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Mechanism of Action
Inactivates or alters bacterial ribosomal proteins and other macromolecules that may interfere with metabolism and cell-wall synthesis
Absorption
Well absorbed; macrocrystalline form absorbed more slowly due to slower dissolution (causes less GI distress)
Bioavailability: Increased with food
Distribution
Crosses placenta, but not well distributed
Protein bound: Approximately 60-90%
Vd: 0.8 L/kg
Metabolism
Reduced by bacterial flavoproteins to reactive intermediates
Body tissues (except plasma) metabolize 60% of drug to inactive metabolites
Elimination
Half-life: 20-60 min; prolonged with renal impairment
Excretion: Urine (40%); feces (small amounts)
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| nitrofurantoin oral - | 25 mg/5 mL suspension |  | |
| nitrofurantoin oral - | 25 mg/5 mL suspension |  | |
| nitrofurantoin oral - | 25 mg/5 mL suspension |  |
Copyright © 2010 First DataBank, Inc.
Patient Handout
nitrofurantoin oral
NITROFURANTOIN - ORAL
(NYE-troe-fure-AN-toyn)
COMMON BRAND NAME(S): Macrodantin
USES: This medication is used to treat or prevent certain urinary tract infections.This medication is an antibiotic that works by stopping the growth of bacteria. It will not work for viral infections (such as common cold, flu). Unnecessary use or overuse of any antibiotic can lead to its decreased effectiveness.Nitrofurantoin should not be used by children less than one month of age due to the risk of a certain blood problem (hemolytic anemia).
HOW TO USE: Take this medication by mouth with food or milk as directed by your doctor. This medication is usually taken four times daily to treat an infection or once daily at bedtime to prevent infections. Swallow the medication whole. Avoid using magnesium trisilicate-containing antacids while taking this medication. Magnesium trisilicate-containing antacids bind with nitrofurantoin, preventing its full absorption.Dosage and duration is based on your medical condition and response to therapy. For children, the dosage is also based on body weight.For the best effect, take this antibiotic at evenly spaced times. To help you remember, take this medication at the same time(s) every day.When taking this medication to prevent infection, take it exactly as directed by your doctor. Do not skip doses or stop taking it without your doctor's approval. Inform your doctor if you notice signs of a new urinary tract infection (such as pain while you are urinating).If you are taking this medication to treat an infection, continue to take this medication until the full prescribed amount is finished, even if symptoms disappear after a few days. Stopping the medication too early may result in a return of the infection.Inform your doctor if your condition lasts or gets worse.
SIDE EFFECTS: Nausea, vomiting, loss of appetite, or headache may occur. Take this medication with food to help minimize nausea. If any of these effects last or get worse, notify your doctor or pharmacist promptly.This medication may cause your urine to turn dark yellow or brown in color. This effect is harmless and will disappear when the medication is stopped.Remember that this medication has been prescribed because your doctor has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.This medication may rarely cause very serious (possibly fatal) lung problems. Lung problems may occur within the first month of treatment or after long-term use of nitrofurantoin (generally for 6 months or longer). Get medical help right away if you develop symptoms of lung problems, including: cough that doesn't go away, chest pain, shortness of breath/trouble breathing, joint/muscle pain, bluish/purplish skin.Tell your doctor right away if you have any serious side effects, including: headache that is severe or doesn't go away, new signs of infection (such as sore throat that doesn't go away, fever), easy bruising/bleeding, mental/mood changes, vision changes.This drug may rarely cause serious (possibly fatal) liver disease, blood or nerve problems. Tell your doctor right away if you notice any of the following serious side effects: nausea/vomiting that doesn't stop, unusual tiredness, dark urine, yellowing of eyes/skin, fast/pounding heartbeat, numbness/tingling of the arms/legs, muscle weakness.This medication may rarely cause a severe intestinal condition due to a bacteria called C. difficile. This condition may occur during treatment or weeks to months after treatment has stopped. Tell your doctor right away if you develop: diarrhea that doesn't stop, abdominal or stomach pain/cramping, blood/mucus in your stool.If you have these symptoms, do not use anti-diarrhea or opioid products because they may make symptoms worse.Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection (such as oral or vaginal fungal infection). Contact your doctor if you notice white patches in your mouth, a change in vaginal discharge, or other new symptoms.A very serious allergic reaction to this drug is rare. However, get medical help right away if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.In the US -Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088 or at www.fda.gov/medwatch.In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
PRECAUTIONS: Before taking nitrofurantoin, tell your doctor or pharmacist if you are allergic to it; or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. Talk to your pharmacist for more details.Before using this medication, tell your doctor or pharmacist your medical history, especially of: kidney disease, liver disease (including liver problems caused by nitrofurantoin in the past), a certain genetic condition (G-6-PD deficiency), certain blood disorders (such as anemia), lung diseases, certain nerve problems (peripheral neuropathy), certain eye diseases (optic neuritis), diabetes, untreated mineral imbalance, vitamin B deficiency.Nitrofurantoin may cause live bacterial vaccines (such as typhoid vaccine) to not work well. Tell your health care professional that you are using nitrofurantoin before having any immunizations/vaccinations.Older adults may be at a greater risk for side effects while using this drug, especially nerve, liver or lung problems.During pregnancy, this medication should be used only when clearly needed. This medication should not be used if you are near or at the time of delivery (weeks 38-42 of pregnancy) due to possible harm to the newborn, such as a certain blood problem (hemolytic anemia). Discuss the risks and benefits with your doctor.This medication passes into breast milk and may have undesirable effects on nursing infants less than one month old and infants with a certain genetic condition (G-6-PD deficiency). Consult your doctor before breast-feeding.
DRUG INTERACTIONS: See also the How to Use section.Drug interactions may change how your medications work or increase your risk for serious side effects. This document does not contain all possible drug interactions. Keep a list of all the products you use (including prescription/nonprescription drugs and herbal products) and share it with your doctor and pharmacist. Do not start, stop, or change the dosage of any medicines without your doctor's approval.A product that may interact with this drug is: sulfinpyrazone.This medication may interfere with certain lab tests (such as certain urine glucose tests), possibly causing false test results. Make sure lab personnel and all your doctors know you use this drug.
OVERDOSE: If someone has overdosed and has serious symptoms such as passing out or trouble breathing, call 911. Otherwise, call a poison control center right away. US residents can call their local poison control center at 1-800-222-1222. Canada residents can call a provincial poison control center.
NOTES: Do not share this medication with others.This medication has been prescribed for your current condition only. Do not use it later for another infection unless your doctor tells you to.Lab and/or medical tests (such as complete blood counts, tests for kidney and liver function, urine cultures) should be done while you are taking this medication. Keep all medical and lab appointments. Consult your doctor for more details.
MISSED DOSE: If you miss a dose, take it as soon as you remember. If it is near the time of the next dose, skip the missed dose. Take your next dose at the regular time. Do not double the dose to catch up.
STORAGE: Store at room temperature away from light and moisture. Do not store in the bathroom. Keep all medications away from children and pets.Do not flush medications down the toilet or pour them into a drain unless instructed to do so. Properly discard this product when it is expired or no longer needed. Consult your pharmacist or local waste disposal company.
Information last revised September 2023. Copyright(c) 2023 First Databank, Inc.
IMPORTANT: HOW TO USE THIS INFORMATION: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
